Moberg Pharma AB (Formerly known as Moberg Derma) Reports Positive Interim Results In Phase II Clinical Study Of MOB-015

STOCKHOLM--(BUSINESS WIRE)--Regulatory News:

Moberg Pharma AB (OMX:MOB)(STO:MOB) today announced positive interim results from its ongoing phase ll study of MOB-015. After six months of treatment with MOB-015, 40 per cent of the patients were mycologically cured and no safety concerns were identified. MOB-015 is a novel topical formulation of terbinafine for the treatment of nail fungus (onychomycosis).

Help employers find you! Check out all the jobs and post your resume.